Akash Maniam: Which patients need further intensification in addition to an ARSI?

Akash Maniam, Clinical Director at Caribbean Cancer Research Institute (CCRI), shared a post by International Urology Cancer Summit on LinkedIn:

“As expected, ADT + daro outperforming ADT. Of course, seeing modern trials incorporating ADT + ARSI doublets as the control arm to reflect current standards of care is the priority.

Still, the key debate remains – which patients need further intensification in addition to an ARSI – e.g with docetaxel, PARPi or Lu-PSMA? Look forward to STAMPEDE2 and other trials which would help shape our 1st-line understanding. ”

Quoting International Urology Cancer Summit’s post:

“With the potential availability of the fourth ‘musketeer‘ in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), how will clinicians decide on the best therapeutic approach moving forward?

As new options like darolutamide in combination with androgen deprivation therapy become available, understanding the criteria for treatment selection becomes even more critical. What factors will guide our decisions in this evolving landscape?”